



THE PATH TO GENOMIC MEDICINE: AN IMPLEMENTATION CHALLENGE

Lori A. Orlando, MD MHS

POTENTIAL TO CHANGE THE HEALTHCARE PARADIGM



From <https://en.wikipedia.org/wiki/Metabolomics>



IT IS NOT WITHOUT RISKS



Eugenics
Determinism

REAL QUESTION IS: HOW TO IMPLEMENT?

CHALLENGES

- Complex
- Interventions vary widely
- Context dependent
- Highly diverse stakeholders



IMPLEMENTATION RESEARCH

Implementations without structure provide no guidance on implementation in other settings–

- Lack generalizability
- Lack sustainability


**ONE-OFF
SOLUTIONS**

EXAMPLE: CENTRAL LINE INFECTIONS


- Peter Pronovost's ICU checklist (NEJM 2006)
- 108 ICUs in Michigan
- Catheter related infections decreased by 80% at all sites



HOW YOU GET TO OUTCOMES IS IMPORTANT




HOW YOU GET TO OUTCOMES IS IMPORTANT



CONSOLIDATED FRAMEWORK FOR IMPLEMENTATION RESEARCH (CFIR)

Overall:
26
constructs
13 sub-
constructs

The Consolidated Framework for Implementation Research (CFIR)



(Damschroder L.J. et al ;2009)

Conceptual Framework- Translating Genomic Discoveries in Diverse Populations

Interventions

Purpose: Evaluate
- Disease risk, Dx, Prognosis, Therapy

Type: Family history, SNP-panel, targeted, whole genome, exome sequencing, cascade

Comparator: none, usual care, another intervention

Education:
- patient, family, provider

Return of Results:
-By : clinicians, genetic counselors, lay persons
-To: patient, family, provider
- How: In person, app, EHR, telemedicine
- What: Structure, content of report including what will be returned

Characteristics:
-Cost, relative advantage, evidence strength, adaptability, complexity

IMPLEMENTATION PROCESS

Select steps taken to facilitate uptake using expert recomm. for implementing change study choices (in sparks)

Potential Mitigating Factors

Outer Setting

PHYSICAL CONTEXT

Medical: Access, available quality of care
Built Environment: Housing, poverty, crime, walkability, pollution, food
Unequal Distribution of Resources: Money, Public Policy, Systems, Education

Inner Setting

MEDICAL CONTEXT

Setting Type: in/outpatient, academic/community, rural/urban, private/safety
Health Systems: patient population (#/year, payor mix, EHR type, race/ethnicity, SES)
Implementation Climate: Readiness, access to resources & information, compatibility with workflow, leader engagement, tension for change

PROCESSES

Communication: Patient, family, provider, lab (nature and quality)
Laboratory: Quality metrics, turn around, structural variant calling, ROR process

Individuals

PATIENT FACTORS

Social: Social network, support, influence, engagement
Demographic: Age, race/ethnicity, sex/gender, lang., literacy, numeracy, income, employment, education, insurance
Psychosocial: Depression, stress, anxiety, self-efficacy, perceived racism, activation, cultural norms, family issues
Stressors/Resources: Family, community, occupational, financial
Behavioral: Lifestyle, self-management, adherence, health seeking
Attitude, Understanding: Genetic testing, return of results, about intervention, trust (in testing, results, providers), expected utility, preference for who returns results
Biological/genetic makeup: Family history, Health history, Ancestry

PROVIDER FACTORS

Demographic: Age, Race/Ethnicity, Sex/gender, Training, Experience, Specialty
Psychosocial: Stress, satisfaction, anxiety from medical uncertainty
Stressors/Resources: Time, access to information, experts, referrals
Behavioral: Communication style, implicit bias, cultural appropriateness
Attitude, Understanding: Genetic testing, value of intervention, return of results, expected utility, ability to appropriately use the intervention (self-efficacy)

Outcomes

Clinical Utility:

Actionability of intervention
Diagnostic yield
Health Status, QOL, Morbidity
Mortality
Patient uptake of intervention recs
Provider uptake of intervention recs
Patient achieves study endpoint

Psychological Utility:

health behaviors, anxiety, distress, depression

Pragmatic Utility:

Life and reproductive planning

Intervention Adoption:

Patient (reach)
Uptake by clinic, health system, provider (adoption)
Adherence to intervention

Social Utility & Maintenance :

Healthcare Utilization
Effectiveness >6 months
Sustained delivery of intervention
Uptake by payors
Cost effectiveness

INTERMED. OUTCOMES (RESULTS)


Biological/Clinical: Processes and markers

1° & 2° Findings:

Pathogenicity, findings, Iterative phenotyping, Follow up

Stakeholder Engagement

EX. IMPLEMENT RISK ASSESSMENT PROGRAM



KEY CHALLENGES FOR GENOMIC MEDICINE


There are many but will highlight 4 areas:

- 1) Intervention complexity
- 2) Disparities
- 3) Data (type and ownership)
- 4) Implementation outcomes


INTERVENTION COMPLEXITY

- Family health history, genotyping, WES/WGS ?
 - Current guidelines recommend using FHH to guide testing
 - ~ 50% with pathogenic BRCA do not meet testing criteria
 - New knowledge makes genotyping results outdated in few years
 - Monogenic highly pathogenic variants are not 100% penetrant (why?)
 - FHH x gene interactions (PALB2) (*Antoniou. N Engl J Med 2014; 371:497-506*)
- Who will collect the FHH?
- Who will analyze FHH to know when to test?
- Who will perform the testing and explain the testing to the patient?
- Who and how will results be documented and returned to patient?

PROPOSED FHH-BASED RISK ASSESSMENT



EX. IMPLEMENT RISK ASSESSMENT PROGRAM



DISPARITIES


- Social determinants of health
- Trust
- Ancestry
- Insurance coverage
- Type of accessible medical providers and clinics
- Resources for performing testing or return of results

(Manrai N Engl J Med 2016; 375:655-665)


FHH IMPLEMENTATION ADAPTATION

Each step contains several implementation strategies that each site could select based upon their context.

1. Access to risk assessment via linkage from EMR, stand alone web server, phone
2. Testing via health system lab, mailed samples to lab, online servicing
3. Genetic counseling via GC or lay person trained in returning results, in person vs tele-counseling



EX. IMPLEMENT RISK ASSESSMENT PROGRAM



PATIENT DATA (RISK INFORMATION)

- Are risks interpreted differently if it is family history or DNA?
- Does sharing with relatives change for family history vs DNA?
- Do relatives react differently to family history vs DNA?
- Does it change their likelihood of acting on risk information?

Who prefers which method and how do we predict response

PATIENT DRIVEN CLOUD PLATFORM

PATIENTS SHOULD HAVE THE OPTION TO OWN THEIR DATA


Not all patients want their data but those who do, should

PHRs so far have been limited and dysfunctional

- E-patient Dave in 2009 lead to Google Health's closure in 2011


Advances in informatics and data standards

- SMART – FHIR
- Blockchain



Blockchain: Securing Internet of Medical Things (IoMT) - Scientific Figure on ResearchGate. Available from: https://www.researchgate.net/figure/Internet-of-Medical-Things-IoMT_fig1_330883527 [accessed 21 Jun, 2019]

EX. IMPLEMENT RISK ASSESSMENT PROGRAM



OUTCOMES TO EVALUATE IMPACT



Reach (patient uptake)	80%
Effectiveness	80%
Adoption (provider uptake)	80%
Implementation fidelity	80%
Maintenance	80%

End result: intervention helps 32% of those who could benefit from it
Context: will further mediate this impact (most likely for the worse)

SUMMARY

- Genomic Medicine has tremendous potential to transform healthcare for the better
- There are numerous pitfalls that could lead to misuse, misalignment, and the possibility of harm
- An implementation sciences framework can help anticipate, evaluate, and understand facilitators and barriers to clinical use of genomics and help guide optimal implementations that are tailored to the setting